Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1465848 | 0.80 | — | — | |
| SCHEMBL6701853 | 0.79 | ALDH1A1 (0.32) | ALDH1A1TDP1CA2CA1CA12 | |
| SCHEMBL4610096 | 0.79 | IDO1 (0.35) | ALDH1A1CA2CA1CYP3A4ALOX15 | |
| SCHEMBL4298018 | 0.78 | APOBEC3G (0.32) | GABRA1 | |
| SCHEMBL2082916 | 0.75 | LMNA (0.38) | TSHRALDH1A1TDP1CA2CA1 | |
| SCHEMBL6252367 | 0.75 | — | — | |
| SCHEMBL4611395 | 0.74 | PDE2A (0.33) | — | |
| SCHEMBL4609578 | 0.74 | PDE2A (0.33) | — | |
| SCHEMBL4609739 | 0.74 | PDE2A (0.33) | — | |
| SCHEMBL28236194 | 0.72 | GABRA1 (0.60) | GABRA1GABRB2TSHRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856278-B2 | Lysophosphatidylserine derivative | THE UNIVERSITY OF TOKYO (JP) | 2018-01-02 | — | — | US | disclosed |
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2017-07-27 | — | — | US | disclosed |
| EP-1846354-B1 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES FOR THE TREATMENT OF OCULAR HYPERTENSIVE CONDITIONS | ALLERGAN INC (US) | 2010-04-28 | — | — | EP | disclosed |
| US-7635716-B2 | Substituted cyclopentanes or cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7405240-B2 | Substituted cyclopentanes or cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080119560-A1 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080058414-A1 | Substituted Cyclopentanes Or Cyclopentanones As Therapeutic Agents | ALLERGAN, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7323591-B2 | Substituted cyclopentanes or cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070265464-A1 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES AS THERAPEUTIC AGENTS | OLD DAVID W | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119560-A1 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES AS THERAPEUTIC AGENTS | PDE3A, PTGIR, PTGIS | GABRA1 1730/4885GABRB2 1055/4885TSHR 3900/4885 |
| US-20080058414-A1 | Substituted Cyclopentanes Or Cyclopentanones As Therapeutic Agents | CYC1, HSPE1, CYP27A1 | GABRA1 968/4885GABRB2 651/4885TSHR 3306/4885 |
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | LPAR3, LPAR1, LPAR4 | GABRA1 1291/4885GABRB2 1717/4885TSHR 526/4885 |
| US-20070265464-A1 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES AS THERAPEUTIC AGENTS | HCCS, MCL1, NME4 | GABRA1 2144/4885GABRB2 1393/4885TSHR 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.